LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY

Background. This work is a comparative study of survival in patients with stage III A non-small cell lung cancer (NSCLC) treated with neoadjuvant chemoradiotherapy (NCRT), neoadjuvant chemotherapy (NCT) and neoadjuvant chemotherapy and adjuvant radiation therapy (NCT + adjuvant RT).Material and methods. Three groups of 65 people were selected. The first group received NCT, the second group - NCT, and the third group - NCT + adjuvant radiation therapy. The NCRT group received radiation therapy of 30 Gy. Survival was assessed using the Kaplan and Mayer scale and according to the log rank criteria.Results. The statistical criterion for NCRT in relation to NCT was-3.51279, r=0.00044. The statistical criterion for NCRT in relation to NCT + adjuvant RT was-2.88568, r=0.00391. Less reliable dependence was observed between NCT and NCT + adjuvant RT (the statistical criterion =1.809508, p=0.070307).Conclusions. Performing NCT, NCRT or NCT + RT and the status of complete morphological response (CMR) during the revision of histological material, it is possible to predict survival for a period of up to 36 months. NCRT is the optimal method of treatment.